Eli lily obesity pilli orforglypron caused 12% weight loss

Ely Lily Thursday said the highest doses of that Daily In the late-phase test, 72 weeks, their body weight was reduced by about 12% or approximately 27 pounds, freeing the way to enter the market.

Some doctors said the result appears to be comparable, if there is no shortage of weight loss Novo NordisBlockbuster Weekly GLP -1 injection for obesity, Vegovi.

According to some Wall Street Analysts expected Aelly Lily’s oral GLP -1, the weight loss is about 15%of the weight loss. Some doctors also recorded the number of patients at the highest dose of the pill, which stopped the treatment due to side effects or any other reasons.

Nevertheless, other doctors appreciated the potential for reaching new patients and the possibility of pills, such as needles.

Medical Director of the Wet Welfare Program of UT Southwestern Medical Center. Jaime Almandoj said, “This is a strong and promising result for an oral agent.

He continued, “Injectabals have set a high bar, but this study strengthens the probability of obesity to the oral GLP -1, especially the patients who are hesitant to start or maintain injectable treatment,” he added.

Dr. Johns Hopkins Community Physician Director of the Andocrine Hospitalist Dr. Mihail “Misha” Zimbermint said that the pill is the ability to become a game changer, as long as people can withstand side effects. “

The results of the test are one of the most closely viewed studies in the pharmaceutical industry and follow Positive data in April Test of phase three Examination of experimental pill in diabetes patients. They bring the heel lily’s pill, orforgliprn, to lose weight and to be a new, needle -free option in the first new, needle -free option for diabetes called GLP -1S.

Eli Lily is expected to submit data to the regulators at the end of the year, plans to start the bullet in 226, in an interview by Lily Cardiometabolic Health President Ken Customer.

That launch can basically change the space, help more patients access treatment, and reduce the lack of existing injection supply. The more convenient and easy -to -make pill can help ellly Lily to strengthen your dominance in the growing section, as other drug manufacturers, the main rival Novo Nordisk, the race to launch weight loss pills.

Castor said that injected obesity and diabetes drugs are approximately 8 million patients, but probably about 170 million those who could benefit from the drug.

He said, “To fulfill this demand, we include oral molecules like Orforglipron, which use different tools of product and are not required as a sophisticated supply chain to deliver it to patients,” he said.

Professor of Medicine at Florida University and Program Director of Obesity Medicine Fellowship. The Amy Share said that she hopes that the pill will be less expensive than existing injections, which are mainly expensive because of the incoming devices. She said that low prices can help to relieve obstacles to enter patients, possibly ready to produce the drug over the drug.

Many insurers still do not cover GLP -1 for obesity. Vegovi and other drugs have approximately $ 1000 prices before insurance.

Drigham and women’s hospital weight management and well -being co -director, said that more patients stopped shooting due to side effects compared to the existing GLP -1S in the market. Powered by Blogger. The weekly obesity injection of Vegovi and Eli Lily is caused by the side effects of late-step tests on the injection zipbound .This are the rates of distraction due to the side effects About 7% Or less.

She mentioned that almost a quarter of the pills stop the treatment for any reason, warning that the excitement for Orforglipron should be increased “because you get all this enthusiasm, and then the pill comes out and no one can take it.”

It is unclear that, in addition to the side effects, those patients closed the pill.

But the University of Florida said that she does not believe that the closure of the shutdown or the side effects will be a crucial factor for doctors.

She believes that an oral alternative is that writing GLP -1 to patients can make more therapists more convenient. Some physicians are currently hesitant to write injections because they do not know how to use them to use them, “Sardar said.

Almandoj said the prescribed decisions depend on the patient’s specific needs and preferences as well as access and affordability. Injected GLP -1 may be a preferred option for patients who have high weight loss rates or health problems caused by cardiovascular diseases and cardiovascular diseases and metabolic disorders.

But for those who have a logical challenge with “simplicity or convenience or injection or injection, oral GLP -1 may be the best fit.”

Detailed results of the test will be presented at the European Medical Meeting in September and published in the head of the chieftains. The more phase of this pill will be shared by the end of this year, with adult studies that have obesity or weight, and type 2 diabetes.

To reduce weight and regulate blood sugar, the intestinal hormone called GLP -1 is a targeting of the GLP -1, Eli Lily’s pill, Orforglipron, and Novo Nordisk’s diabetes pill all work. But like those other drugs, heel lily pill is not a peptide drug. This means that it is more easily absorbed into the body and does not require dietary restrictions such as ribabelsus.

Eli Lily is currently three years older than other drug manufacturers, including Fiezer, Astragenecca, Roche, Structure therapist And Wyking therapypicsGoogenhem analyst Seema Fernandez previously CNBC.

Some analysts expect that the GLP -1 market price will be more than $ 150 billion annually. Oral GLP -1, the total billion of them could increase $ 50 billion, Fernandes said.

– CNBC’s Angelica Pebals contributed to the report.